On this episode of The Ellis Martin Report on the MoneyTalk Radio Network, Ellis Martin speaks with Dustin Haines, Chief Executive Officer of Echo IQ Limited (ASX:EIQ) (OTCMKTS:ECHQF).

In this edition of The Ellis Martin Report and Money Talk Radio, we sit down with Shaun Bagai, Chief Executive Officer of RenovoRx, Inc. (NASDAQ:RNXT), a clinical-stage biopharmaceutical company pioneering a targeted, localized approach to treat hard-to-reach cancers.

AFT Pharmaceuticals Limited (NSX:AFT) (ASX:AFP) today reports it has again achieved another year of record revenue with annual sales exceeding $200 million1 and it is now firmly focused on its revenue target of $300 million by the end of the 2027 financial year.

TruScreen Group Limited (ASX:TRU) (NZE:TRU) advises that it has re-entered the Indian subcontinent with the appointment of India medical products distributor Renovate Biologicals Pvt Ltd to distribute its unique AI enabled TruScreen cervical cancer screening system in India.

TruScreen Group Limited (NZE:TRU) (ASX:TRU) is pleased to provide an update of its key markets and target markets.

Apiam Animal Health Limited (ASX:AHX) is pleased to provide an update on Apiam Animal Health's year-to-date performance for FY24 up until 31 March 2024 (FY24 YTD).

Apiam Animal Health Limited (ASX:AHX) MD Dr. Chris Richards Speaks with ABN Newswire on Revenue Growth in the Business and the consolidation of acquisitions made by the company over the last two years.

Apiam Animal Health Limited (ASX:AHX) today released its financial results for the six-months ended 31 December 2023 (H1 FY24).

Apiam Animal Health Limited (ASX:AHX) will release its financial results for the six months ended 31 December 2023 (H1 FY24) on Friday February 23, 2024.

Apiam Animal Health Limited (ASX:AHX) today announced an update on the Company's performance for the quarter ended 30 September 2023 (Q1 FY24).